Jubilant Life Sciences has reported results for third quarter ended December 31, 2012.
The company, on consolidated basis, has reported net profit of Rs 26.69 crore for the quarter as compared to a net loss of Rs 78.39 crore for the same quarter in the previous year. Total income from operation of the company has increased by 19.27% at Rs 1306.39 crore for quarter under review as compared to Rs 1095.25 crore for the quarter ended December 31, 2011.
Jubilant Life Sciences is an integrated Pharmaceuticals and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution provider out of India.
